SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
Por:
Garcia-Campelo, R, Sullivan, I, Arriola, E, Insa, A, Vidal, O, Cruz-Castellanos, P, Moran, T, Reguart, N, Zugazagoitia, J, Domine, M
Publicada:
1 sep 2023
Ahead of Print:
1 jul 2023
Resumen:
Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum-etoposide adjuvant therapy, although only a minority of patients with SCLC qualify for surgery. Concurrent chemo-radiotherapy is the standard of care for LS-SCLC that is not surgically resectable, followed by prophylactic cranial irradiation (PCI) for patients without progression. For extensive-stage (ES)-SCLC, a combination of platinum and etoposide has historically been a mainstay of treatment. Recently, the efficacy of programmed death-ligand 1 inhibitors combined with chemotherapy has become the new front-line standard of care for ES-SCLC. Emerging knowledge regarding SCLC biology, including genomic characterization and molecular subtyping, and new treatment approaches will potentially lead to advances in SCLC patient care.
Filiaciones:
Garcia-Campelo, R:
Hosp Univ A Coruna, Hlth Res Inst, INIBIC, Dept Med Oncol, La Coruna, Spain
Sullivan, I:
IIB St Pau, Hosp Santa Creu & St Pau, Dept Med Oncol, Barcelona, Spain
Arriola, E:
Hosp del Mar, CIBERONC, Dept Med Oncol, Barcelona, Spain
Insa, A:
Hosp Clin Valencia, Dept Med Oncol, Valencia, Spain
Vidal, O:
Hosp Univ & Politecn La Fe Valencia, Dept Med Oncol, Valencia, Spain
Cruz-Castellanos, P:
Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
Moran, T:
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol Badalona, Inst Germans Trias & Pujol, Dept Med Oncol,Badalona Appl Res Grp Oncol, Barcelona, Spain
Reguart, N:
Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
Zugazagoitia, J:
Hosp Univ 12 Octubre, Tumor Microenvironm & Immunotherapy Res Grp, Dept Med Oncol, Madrid, Spain
Hlth Res Inst Hosp Univ 12 Octubre I 12, H12O CNIO Lung Canc Clin Res Unit, Hlth Res Inst, CIBERONC, Madrid, Spain
Domine, M:
Univ Autonoma Madrid, Hosp Univ Fdn Jimenez Diaz, Dept Med Oncol, IIS FJD,Oncohealth Inst, Madrid, Spain
Univ Autonoma Barcelona, Barcelona, Spain.
hybrid, All Open Access, Hybrid Gold
|